Methylation status of nine tumor suppressor genes in multiple myeloma
Abstract Aberrant methylation in promoter-associated CpG islands has been recognized as a major mechanism for tumor suppressor gene silencing in several malignancies. We determined the methylation status of nine tumor suppressor genes in 68 newly diagnosed MM patients by methylation-specific PCR. The frequency of promoter hypermethylation for individual genes was: CDH1, 50%; p16INK4a, 42.8%; p15INK4b, 16.2%; SHP1, 14.7%; ER and BNIP3, 13.2%; RARβ, 11.8%; DAPK 5.9%; and MGMT 0%. Overall, 79% of patients presented at least one hypermethylated gene. By univariate analysis, hypermethylation of DAPK (P < 0.001) and RARβ (P = 0.01) genes were identified as adverse prognostic features. Median OS of patients with hypermethylation in DAPK (4 months) and RARβ (34 months) was significantly lower than in patients without hypermethylation (median survival not reached), with values of P < 0.001 and P = 0.01, respectively. Our data suggest that DAPK and RARβ hypermethylation are adverse prognostic factors in MM. The relevance of these findings as poor prognosis indicators requires confirmation in a larger sample with longer follow-ups..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:91 |
|---|---|
| Enthalten in: |
International journal of hematology - 91(2009), 1 vom: 26. Dez., Seite 87-96 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Braggio, Esteban [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Japanese Society of Hematology 2009 |
|---|
| doi: |
10.1007/s12185-009-0459-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR025103717 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR025103717 | ||
| 003 | DE-627 | ||
| 005 | 20230519164553.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2009 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12185-009-0459-2 |2 doi | |
| 035 | |a (DE-627)SPR025103717 | ||
| 035 | |a (SPR)s12185-009-0459-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Braggio, Esteban |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Methylation status of nine tumor suppressor genes in multiple myeloma |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Japanese Society of Hematology 2009 | ||
| 520 | |a Abstract Aberrant methylation in promoter-associated CpG islands has been recognized as a major mechanism for tumor suppressor gene silencing in several malignancies. We determined the methylation status of nine tumor suppressor genes in 68 newly diagnosed MM patients by methylation-specific PCR. The frequency of promoter hypermethylation for individual genes was: CDH1, 50%; p16INK4a, 42.8%; p15INK4b, 16.2%; SHP1, 14.7%; ER and BNIP3, 13.2%; RARβ, 11.8%; DAPK 5.9%; and MGMT 0%. Overall, 79% of patients presented at least one hypermethylated gene. By univariate analysis, hypermethylation of DAPK (P < 0.001) and RARβ (P = 0.01) genes were identified as adverse prognostic features. Median OS of patients with hypermethylation in DAPK (4 months) and RARβ (34 months) was significantly lower than in patients without hypermethylation (median survival not reached), with values of P < 0.001 and P = 0.01, respectively. Our data suggest that DAPK and RARβ hypermethylation are adverse prognostic factors in MM. The relevance of these findings as poor prognosis indicators requires confirmation in a larger sample with longer follow-ups. | ||
| 650 | 4 | |a Multiple myeloma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hypermethylation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a MSP |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Maiolino, Angelo |4 aut | |
| 700 | 1 | |a Gouveia, Maria E. |4 aut | |
| 700 | 1 | |a Magalhães, Roberto |4 aut | |
| 700 | 1 | |a Souto Filho, João T. |4 aut | |
| 700 | 1 | |a Garnica, Márcia |4 aut | |
| 700 | 1 | |a Nucci, Marcio |4 aut | |
| 700 | 1 | |a Renault, Ilana Zalcberg |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of hematology |d Tokyo [u.a.] : Springer, 1995 |g 91(2009), 1 vom: 26. Dez., Seite 87-96 |w (DE-627)SPR025085697 |w (DE-600)2028991-1 |x 1865-3774 |7 nnns |
| 773 | 1 | 8 | |g volume:91 |g year:2009 |g number:1 |g day:26 |g month:12 |g pages:87-96 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12185-009-0459-2 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 91 |j 2009 |e 1 |b 26 |c 12 |h 87-96 | ||